Geron posts Q3 RYTELO revenue of $28.2M; secures up to $375M in financing

GERON CORP

2024-Q3 EPS reported -$0.23 revenue$29,457,000

Net product revenue of $28.2M from RYTELO in first full quarter of U.S. launch.
Net loss of $26.4M ($0.04 per share) vs. $44.8M loss in Q3 2023.
Total operating expenses guidance for FY2024 set at $260M–$270M.
Received $250M gross proceeds: $125M from Royalty Pharma, $125M from Pharmakon loan.
Additional $125M debt available; $86.5M Hercules loan repaid and terminated.

item 1.01 item 1.02 item 2.01 item 2.02 item 2.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.